Law360, New York (February 19, 2015, 10:53 AM EST) -- On Jan. 30, 2015, in Pom Wonderful LLC v. Federal Trade Commission, the D.C. Circuit handed down a decision that will meaningfully impact how companies advertise their products' health benefits to consumers. In Pom, the D.C. Circuit sided with the FTC in finding that, when a company makes specific claims that its products' health benefits are scientifically "established," it must have "competent and reliable scientific evidence" to substantiate these claims — specifically, at least one randomized controlled trial, the gold standard in the medical and scientific fields. A company relying on studies that do not meet this gold standard, such as Pom Wonderful, risks being charged with false or misleading advertising by the FTC....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
